BIOVERSYS APPOINTS NEW CHIEF FINANCIAL OFFICER

Basel, Switzerland. November 01, 2023, 9am CET

Hernan Levett joins BioVersys AG as new CFO to support the next stage of corporate development

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that Hernan Levett will join the company as its Chief Financial Officer and member of the Executive Team effective immediately.

Hernan Levett brings almost three decades of finance and management experience from both private and publicly listed companies, with more than twenty years within the pharma and biotech sector. He joins BioVersys from SIX-listed Spexis AG, where he served as CFO for the past four years and also oversaw IR, IT & Administration, as well as key business development projects.

Prior to joining Spexis, Mr. Levett was CFO for Nasdaq-listed Auris Medical and served as Head of Group Controlling at Acino Pharma and as VP of Finance & Admin Europe of InterMune. He had developed his international career and finance skills at Novartis, where he served for more than ten years and in several country, regional and HQ units as CFO, in financial planning & controlling, reporting & accounting as well as in treasury functions.

Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys: “As our two lead assets BV100 and Alpibectir (formerly BVL-GSK098) are currently in Phase 2 of clinical development, BioVersys is quickly approaching several important value inflection points over the coming months. We welcome Hernan to the team and look forward to his contributions supporting us on the completion of our ongoing Series C extension and next steps in our financing strategy to ensure the progression of our lead assets and the continued expansion of our pipeline of pathogen-focused products against high priority bacterial infections.”

Hernan Levett: “I am delighted to join the Executive Team of BioVersys and to contribute significantly towards the very exciting next stages of BioVersys’ corporate development, especially in financial operational excellence. I look forward to being part of a high performing organisation by bringing a strong focus on the financial health of the company in order to advance BioVersys’ drug candidates. I am committed to BioVersys’ ambitious goals to address important health threats in AMR and to offer new life-saving therapies to patients in dire need.”

About BioVersys

BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (Alpibectir, Phase 2a, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.

BioVersys contact

Sylvia Mundt, Executive Assistant to CEO, Tel. +41 61 633 22 50; Mail: IR@bioversys.com

Website: www.bioversys.com.